After pooling safety outcomes of ten RCTs enrolling high-risk patients of cardiac disease, the significant findings of this study are: (1) SGLT2-Is are associated with a decreased risk for AKI and ASAEs. This evidence concerns the gene SLC5A2 and acute kidney injury.